Epizyme, Inc. (NASDAQ:EPZM)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as $18.60 and last traded at $18.60, with a volume of 254,057 shares changing hands. The stock had previously closed at $17.55.

Several equities analysts have recently commented on the company. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Leerink Swann restated an “outperform” rating and issued a $28.00 price objective (down from $31.00) on shares of Epizyme in a research report on Wednesday, August 9th. HC Wainwright restated a “buy” rating on shares of Epizyme in a research report on Monday, August 7th. Royal Bank Of Canada set a $20.00 price objective on Epizyme and gave the company a “buy” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Tuesday, July 18th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.38.

The company has a 50 day moving average price of $14.52 and a 200-day moving average price of $15.01. The stock’s market cap is $1.09 billion.

Epizyme (NASDAQ:EPZM) last posted its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.08. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The firm had revenue of $10 million for the quarter, compared to analysts’ expectations of $3.95 million. During the same period last year, the firm earned ($0.49) EPS. The company’s quarterly revenue was up 2027.7% on a year-over-year basis. Analysts anticipate that Epizyme, Inc. will post ($2.39) EPS for the current fiscal year.

In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $14.87, for a total value of $223,050.00. Following the transaction, the insider now directly owns 22,228 shares of the company’s stock, valued at approximately $330,530.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew E. Singer sold 3,024 shares of the firm’s stock in a transaction dated Friday, June 30th. The shares were sold at an average price of $15.50, for a total transaction of $46,872.00. Following the completion of the transaction, the chief financial officer now directly owns 40,529 shares in the company, valued at $628,199.50. The disclosure for this sale can be found here. Insiders sold a total of 48,024 shares of company stock worth $706,722 over the last ninety days. 25.20% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of EPZM. Legal & General Group Plc lifted its stake in Epizyme by 8.9% in the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 795 shares in the last quarter. UBS Asset Management Americas Inc. purchased a new position in Epizyme in the 1st quarter valued at about $175,000. BB&T Securities LLC purchased a new position in Epizyme in the 2nd quarter valued at about $181,000. Trexquant Investment LP purchased a new position in Epizyme in the 2nd quarter valued at about $184,000. Finally, SG Americas Securities LLC lifted its stake in Epizyme by 83.3% in the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 6,072 shares in the last quarter. 83.74% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Epizyme, Inc. (EPZM) Sets New 12-Month High at $18.60” was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/09/epizyme-inc-epzm-sets-new-12-month-high-at-18-60.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.